Withdrawn trial aimed to pit One-Time cell therapy against chemo for Tough-to-Treat lymphoma
NCT ID NCT06313996
Summary
This trial aimed to see if a one-time CAR-T cell therapy (liso-cel) worked better and was safer than standard chemotherapy for adults whose follicular lymphoma had returned or stopped responding to prior treatments. It was a large, global Phase 3 study that would have randomly assigned participants to receive either the new cell therapy or a standard drug regimen. The main goal was to see if the CAR-T therapy could keep the cancer from progressing longer than the standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.